TSTickerStarGet alerts

Sionna Therapeutics Reports Q3 2026 Financial Results; Net Loss of $32.4M

Sionna Therapeutics reported a Q3 2026 net loss of $32.4 million, or $(0.72) per share, compared to a net loss of $20.3 million, or $(0.46) per share, in Q3 2025. Research and development expenses increased to $22.0 million from $16.0 million year-over-year, while general and administrative expenses rose to $12.8 million from $7.8 million. The company ended the quarter with $249.8 million in cash and cash equivalents, which it expects to fund operations into the second half of 2029.

Share this story

Key takeaways

  • Net loss widened to $32.4 million in Q3 2026 from $20.3 million in Q3 2025, driven by increased R&D and G&A spending

  • R&D expenses increased 37.4% year-over-year to $22.0 million, reflecting development expenses, personnel costs, and restructuring-related costs

  • Cash position of $249.8 million as of September 30, 2026, expected to fund operations into the second half of 2029

  • Company plans to initiate AscenSION CF Phase 2 proof-of-concept trial for SION-451 + SION-2222 dual combination in Q1 2027

  • Workforce reduction of approximately 46% implemented in September 2026 to extend operating runway

  • Post hoc analyses of PreciSION CF trial showed mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L when SION-719 was added to Trikafta after excluding three participants with dosing non-adherence

  • Clinical and nonclinical data presented at 2026 North American Cystic Fibrosis Conference supporting advancement of NBD1 stabilizer combinations

Key metrics

Net lossQ3 2026 (three months ended September 30, 2026)
$32.4 million-59.8%
Net loss per share, basic and dilutedQ3 2026
$(0.72)-56.5%
Net lossNine months ended September 30, 2026
$89.1 million-62.5%
Net loss per share, basic and dilutedNine months ended September 30, 2026
$(1.98)-38.5%
Research and development expensesQ3 2026
$22.0 million+37.4%
General and administrative expensesQ3 2026
$12.8 million+64.8%
Cash, cash equivalents, and marketable securitiesAs of September 30, 2026
$249.8 million

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow SION in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert